Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).

The mean percent change in body weight from the obesity cohort from baseline to 52 weeks ranged from −12.3% to −16.2% to −16.2%. | Image Credit: ricka_kinamoto - stock.adobe.com

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

By Sabrina McCrear

July 1st 2025

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down

By Mary Caffrey

June 30th 2025

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.

Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

By Rose McNulty

June 30th 2025

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

CLL cells | Image Credit: © sovova - stock.adobe.com

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

By Jared Kaltwasser

June 30th 2025

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

...

110 111 112 113 114

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions